Restoring Collagen in the Kidney: PS-003 Preclinical Results Announced for Alport Syndrome Gene Therapy
From human podocytes to mice and minipigs, PS-003 research is progressively validating the delivery and expression of the full-length COL4A5 gene. Purespring plans to submit an application for human trials in 2027, but there is no clinical evidence yet that it can preserve patients’ kidney function.